Patents by Inventor David B. Ring
David B. Ring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5811267Abstract: Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell displaying a MDR phenotype. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V.sub.H and V.sub.L domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers.Type: GrantFiled: June 7, 1995Date of Patent: September 22, 1998Assignee: Chiron CorporationInventor: David B. Ring
-
Patent number: 5753204Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a preselected antigen by the binding site of each polypeptide chain when administered to a mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.Type: GrantFiled: June 5, 1995Date of Patent: May 19, 1998Assignees: Chiron Corporation, Creative BioMolecules, Inc.Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
-
Patent number: 5725850Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.Type: GrantFiled: January 11, 1995Date of Patent: March 10, 1998Assignee: Chiron CorporationInventors: Peter Ralph, Kong T. Chong, James Devlin, Robert Zimmerman, Sharon Lea Aukerman, David B. Ring, Sylvia Hsieh Ma
-
Patent number: 5705614Abstract: The present invention relates to a class of molecules called "antigen forks" that inhibit cell growth. These antigen forks possess separate binding elements for two different cell surface antigens and are believed to heterologously crosslink the antigens by binding to them. The two antigens recognized by an antigen fork differ in at least one cellular functional quality, but are simultaneously expressed on the surface of at least one cell type targeted for killing or growth inhibition. The present invention also relates to a method of assay to determine which antibodies may be useful in the preparation of antigen forks.Type: GrantFiled: March 1, 1995Date of Patent: January 6, 1998Assignee: Chiron CorporationInventor: David B. Ring
-
Patent number: 5629197Abstract: Murine monoclonal antibodies are prepared and characterized which bind selectively to high molecular weight mucins by immunoprecipitation test and are IgGs or IgMs. Immunotoxins comprising the monoclonal antibody and cytotoxic moiety were produced.Type: GrantFiled: August 11, 1994Date of Patent: May 13, 1997Assignee: Cetus Oncology CorporationInventors: David B. Ring, Arthur E. Frankel, Michael J. Bjorn
-
Patent number: 5534254Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.Type: GrantFiled: October 7, 1993Date of Patent: July 9, 1996Assignees: Chiron Corporation, Creative BioMolecules, Inc.Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
-
Patent number: 5169774Abstract: Murine monoclonal antibodies, or fragments thereof, that bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.Type: GrantFiled: May 6, 1988Date of Patent: December 8, 1992Assignee: Cetus Oncology CorporationInventors: Arthur E. Frankel, David B. Ring, Walter Laird
-
Patent number: 4958009Abstract: Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID.sub.50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.Type: GrantFiled: July 6, 1987Date of Patent: September 18, 1990Assignee: Cetus CorporationInventors: Michael J. Bjorn, David J. FitzGerald, Arthur E. Frankel, Walter J. Laird, Ira H. Pastan, David B. Ring, Mark C. Willingham, Jeffrey L. Windelhake
-
Patent number: 4956453Abstract: Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.Type: GrantFiled: July 6, 1987Date of Patent: September 11, 1990Assignee: Cetus CorporationInventors: Michael J. Bjorn, Arthur E. Frankel, Walter J. Laird, David B. Ring, Jeffrey L. Winkelhake
-
Patent number: 4938948Abstract: Hybridomas producing monoclonal antibodies suitable for imaging and diagnosis of human breast tumors and such monoclonal antibodies are claimed. The monoclonals are characterized by breast tumor binding range, breast cancer cell line range, and selectivity.Immunoimaging agents comprising the monoclonal antibody and a detectable label, either directly or indirectly conjugated to the antibody are claimed. Methods for imaging breast tumors using the immunoimaging agents are described and claimed.Type: GrantFiled: October 11, 1985Date of Patent: July 3, 1990Assignee: Cetus CorporationInventors: David B. Ring, Arthur E. Frankel
-
Patent number: 4803169Abstract: Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.Type: GrantFiled: February 5, 1986Date of Patent: February 7, 1989Assignee: Cetus CorporationInventors: Peter S. Linsley, Vincent W. Ochs, Diane Horn, Joseph P. Brown, David B. Ring, Arthur E. Frankel
-
Patent number: 4753894Abstract: Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.Type: GrantFiled: January 11, 1985Date of Patent: June 28, 1988Assignee: Cetus CorporationInventors: Arthur E. Frankel, David B. Ring, Michael J. Bjorn
-
Patent number: 4727037Abstract: A method of rapid determination of the isotype class for a panel of monoclonal antibodies is described. The assay comprises adsorbing on a solid support medium antibodies directed to specific immunoglobulin heavy and light chains. Once such isotype-specific antibodies are bound to the nitrocellulose paper, the treated strips can be incubated with the monoclonal antibody of interest. Upon formation of a complex between the specific iso-type antisera and the monoclonal antibody, the complex is visualized by reaction with a chromogenic substance. In the preferred embodiment of the invention, the treated nitrocellulose strips are stored in kit form. Using these prepared strips, the isotyping assay can be performed in less than two hours with a minimum of technical manipulation and expenditure of reagents.Type: GrantFiled: February 15, 1984Date of Patent: February 23, 1988Assignee: Cetus CorporationInventor: David B. Ring
-
Patent number: 4569915Abstract: A P. obtusus strain AU124 having the identifying characteristics of NRRL No. 15595, the strain produces high levels of pyranose-2-oxidase.Type: GrantFiled: February 24, 1984Date of Patent: February 11, 1986Assignee: Cetus CorporationInventor: David B. Ring
-
Patent number: 4568645Abstract: A substantially pure pyranose-2-oxidase preparation obtained from C. versicolor or L. betulinus. The preparation is substantially free of glucosone-utilizing enzyme contaminants having measurable activity at a pH between about 4.4 and 7.0.Type: GrantFiled: February 24, 1984Date of Patent: February 4, 1986Assignee: Cetus CorporationInventors: Kirston E. Koths, Robert F. Halenbeck, David B. Ring